Staging of breast cancer in the neoadjuvant setting.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Research

• Publication date

  2008-08-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-07-6520PMID 18701468PMCID PMC4441792
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetics and Medicine

  2008cited by this paper
• Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.

  2008cited by this paper
• A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling

  2008cited by this paper
• Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy.

  2008cited by this paper
• Gene Expression Signatures to Predict the Development of Metastasis in Breast Cancer

  2007cited by this paper
• Hope and prognostic disclosure.

  2007influential reference
• Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.

  2007cited by this paper
• Use of gene-expression profiling to recommend adjuvant chemotherapy for breast cancer.

  2007cited by this paper
• Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer

  2007cited by this paper
• Oncologist communication about emotion during visits with patients with advanced cancer.

  2007cited by this paper
• Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

  2007cited by this paper
• Gene expression profiling in breast cancer

  2007cited by this paper
• Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

  2006cited by this paper
• Breast Cancer Staging: Working With the Sixth Edition of the AJCC Cancer Staging Manual

  2006cited by this paper
• Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

  2005cited by this paper
• American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.

  2005cited by this paper
• Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.

  2005cited by this paper
• A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

  2004cited by this paper
• A distinct "side population" of cells with high drug efflux capacity in human tumor cells.

  2004cited by this paper
• Putting Gene Arrays to the Test

  2003cited by this paper
• Long-Term Outcome of Neoadjuvant Therapy for Locally Advanced Breast Carcinoma: Effective Clinical Downstaging Allows Breast Preservation and Predicts Outstanding Local Control and Survival

  2002cited by this paper
• Pathobiology of preoperative chemotherapy

  2002cited by this paper
• Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.

  2002cited by this paper
• Cyclin E and survival in patients with breast cancer.

  2002cited by this paper
• Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.

  2002cited by this paper
• Stem cells, cancer, and cancer stem cells

  2001influential reference
• Specific protection against breast cancers by cyclin D1 ablation

  2001cited by this paper
• Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

  1999cited by this paper
• Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.

  1998cited by this paper
• Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

  1998cited by this paper
• Naturally occurring primary deficiencies of the immune system.

  1997cited by this paper
• Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.

  1997cited by this paper
• Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.

  1990cited by this paper
• The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer.

  1978cited by this paper

• Utility of the CPS + EG score with real-life data in patients with breast cancer undergoing neoadjuvant chemotherapy

  2025cites this paper
• Integrated Chemical Array and SERS Profiling of Plasma Small Extracellular Vesicles for Breast Cancer Diagnosis.

  2025cites this paper
• The Effect of the Clinical-Pathological CPS+EG Staging System on Survival Outcomes in Patients with HER2-Positive Breast Cancer Receiving Neoadjuvant Treatment: A Retrospective Study

  2025cites this paper
• Impact of the CPS-EG score as a new prognostic biomarker in triple-negative breast cancer patients who received neoadjuvant chemotherapy

  2024cites this paper
• Accurate breast cancer diagnosis strategy (BCDS) based on deep learning techniques

  2024cites this paper
• Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023.

  2023cites this paper
• Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer

  2023cites this paper
• LINC01605 promotes aerobic glycolysis through lactate dehydrogenase A in triple‐negative breast cancer

  2022cites this paper
• Classification of breast cancer types, sub-types and grade from histopathological images using deep learning technique

  2021cites this paper
• Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice

  2020cites this paper
• CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA

  2020cites this paper
• Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy

  2019cites this paper
• NEMP1 Promotes Tamoxifen Resistance in Breast Cancer Cells

  2019cites this paper
• Study of Carcinoma Breast in Women under 40 Year of age at A Tertiary Care Hospital in Central India

  2018cites this paper
• Evaluation of Prognostic Factors and Validation of Tumor Response Ratios after Neoadjuvant Chemotherapy in Patients with Breast Cancer

  2016cites this paper
• Combination of survivin siRNA with neoadjuvant chemotherapy enhances apoptosis and reverses drug resistance in breast cancer MCF-7 cells.

  2015cites this paper
• Correlation Between Imaging and Pathologic Measurement of Breast Cancer Tumor Size

  2015cites this paper
• Using the Lymph Node Ratio to Evaluate the Prognosis of Stage II/III Breast Cancer Patients Who Received Neoadjuvant Chemotherapy and Mastectomy

  2014cites this paper
• Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer

  2014cites this paper
• Tumor Response Ratio Predicts Overall Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

  2014cites this paper
• The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer

  2013cites this paper
• Pathological controversies in breast cancer: classification of ductal carcinoma in situ, sentinel lymph nodes and low volume metastatic disease and reporting of neoadjuvant chemotherapy specimens.

  2013cites this paper
• Identifying Grade/Stage-Related Active Modules in Human Co-regulatory Networks: A Case Study for Breast Cancer

  2012cites this paper
• Avaliação de resposta patológica em câncer de mama após quimioterapia neoadjuvante: padronização de protocolo adaptado

  2012cites this paper
• Lower Sense of Coherence, Negative Religious Coping, and Disease Severity as Indicators of a Decrease in Quality of Life in Iranian Family Caregivers of Relatives With Breast Cancer During the First 6 Months After Diagnosis

  2012cites this paper
• Prognostic value of axillary lymph node status after neoadjuvant chemotherapy. Results from a multicentre study.

  2011cites this paper
• Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system.

  2011cites this paper
• Neoadjuvant systemic treatment of breast cancer

  2011cites this paper
• Basal-like molecular subtype and HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer.

  2011cites this paper
• Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy.

  2011cites this paper
• Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy

  2011cites this paper
• Nuances and Details of the Pathology Report

  2011cites this paper
• Role of intracellular signalling pathways in conferring resistance to endocrine therapies in breast cancer

  2010cites this paper
• Chimiothérapie néoadjuvante dans les cancers du sein : objectifs, protocoles, évaluation, impacts

  2010cites this paper
• Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy

  2010cites this paper
• The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

  2010cites this paper
• Breast Cancer DNA Methylation Profiles Are Associated with Tumor Size and Alcohol and Folate Intake

  2010cites this paper
• Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.

  2010cites this paper
• Multidisciplinary care for patients with breast cancer.

  2009cites this paper
• Evaluation and Reporting of Breast Cancer after Neoadjuvant Chemotherapy

  2009cites this paper
• [Neoadjuvant systemic therapy in breast cancer].

  2009cites this paper
• EXPRESSION AND RESPONSE TO CHEMOTHERAPY IN BREAST CANCER 1038 for predicting the response to chemotherapy in general and the response to specific chemotherapy regimens in particular

  year unknowncites this paper